Tomiteru Togano
Overview
Explore the profile of Tomiteru Togano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sato S, Sawazaki E, Tsunoda S, Kamata W, Togano T, Tamai Y
Int J Hematol
. 2025 Mar;
PMID: 40057936
Background: The prognostic significance of minimal residual disease (MRD) negativity in multiple myeloma (MM) is well-established, and MRD negativity serves as a surrogate marker for treatment outcomes. However, in various...
2.
Sato S, Tsunoda S, Kamata W, Togano T, Tamai Y
Rinsho Ketsueki
. 2025 Mar;
66(2):92-99.
PMID: 40044178
Combination of immunosuppressive therapy (IST) and thrombopoietin receptor agonists has revolutionized the treatment of aplastic anemia. In this study, 18 patients with eltrombopag (EPAG)-refractory and intolerant AA, including 16 with...
3.
Sato S, Tsunoda S, Kamata W, Togano T, Tamai Y
Blood Res
. 2025 Feb;
60(1):10.
PMID: 39907880
The efficacy and safety of polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisolone (pola-R-CHP) in patients aged ≥ 80 years with untreated diffuse large B-cell lymphoma (DLBCL) remain largely...
4.
Duration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients
Kamegai K, Itoh N, Ishikane M, Iwamoto N, Asai Y, Akazawa-Kai N, et al.
J Infect Chemother
. 2025 Jan;
31(4):102631.
PMID: 39848541
Objective: The duration of viral shedding and criteria for de-isolation in the hospital among immunocompromised patients with coronavirus disease 2019 (COVID-19) remain unclear. This study aimed to evaluate viral shedding...
5.
Sato L, Iwamoto N, Kakumoto Y, Tsuzuki S, Togano T, Ishikane M, et al.
J Atheroscler Thromb
. 2024 Feb;
31(8):1179-1193.
PMID: 38355124
Aim: Several studies have shown the efficacy and safety of low-molecular-weight heparin use in coronavirus disease 2019 (COVID-19), but that of unfractionated heparin (UFH) has not been investigated. We investigated...
6.
Kamegai K, Iwamoto N, Ishikane M, Yamamoto K, Horii K, Kubota S, et al.
Glob Health Med
. 2024 Jan;
5(6):366-371.
PMID: 38162429
Immunocompromised coronavirus disease 2019 patients are at a higher risk of prolonged viral shedding than immunocompetent patients. However, as of August 2023, there is no clear international standard for de-isolating...
7.
Terada M, Saito S, Kutsuna S, Kinoshita-Iwamoto N, Togano T, Hangaishi A, et al.
Life (Basel)
. 2023 Nov;
13(11).
PMID: 38004324
Convalescent plasma therapy, which involves administering plasma from recovered coronavirus disease 2019 (COVID-19) patients to infected individuals, is being explored as a potential treatment for severe cases of COVID-19. This...
8.
Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
Suzuki T, Asai Y, Takahashi K, Sanada M, Shimanishi Y, Terada M, et al.
Heliyon
. 2023 Oct;
9(10):e20568.
PMID: 37842585
Background: We aimed to investigate chronological changes in the characteristics of participants in a coronavirus disease 2019 convalescent plasma donation study that may benefit optimal collection methods in the future....
9.
Saito S, Kutsuna S, Akifumi I, Hase R, Oda R, Terada J, et al.
J Infect Chemother
. 2023 May;
29(9):869-874.
PMID: 37178973
Background: Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19). Despite its use for treating several viral infections, we lack comprehensive data on its efficacy...
10.
Kamo-Imai A, Togano T, Sato M, Kawakami Y, Inaba K, Shimazu H, et al.
Transfus Apher Sci
. 2023 Mar;
62(3):103687.
PMID: 36964059
Purpose: Since 2020, the novel coronavirus infection (COVID-19) has spread globally. A few studies have investigated the safety of COVID-19 convalescent plasma (CCP) apheresis from COVID-19. This study was the...